For an optimal site experience, we recommend using a different browser.
Using Internet Explorer may prevent you from accessing Chubb.com, and some site features may not function as expected.

X
skip to main content

From governments to corporates, the importance of a diversified supply chain has been a big lesson of the pandemic. At the start, the global supply chain was tested as governments around the world urgently tried to buy personal protective equipment (PPE), test kits and other medical devices. With various countries limiting exports of products from drugs to PPE, the tension between national priorities and globalised free markets has become abundantly clear.

For governments, ways to manage health security more closely and bring production of life science products closer to home will be a big question as the dust settles on this pandemic. For life science companies, a focus on local supply and diversification are two key themes in corporate risk mitigation efforts, after experiencing first-hand the risks posed to their supply chains by government interventions, lockdowns and competition for resources.

 

With attention shifting to vaccines, the downstream supply chain is now where some of the most significant risks reside. With some vaccines needing to be stored at very cold temperatures, the pressure is on within the supply chain. If temperatures, among other parameters such as vibration and humidity, are not properly maintained when drugs are transported, it can lead to batches being thrown away.

 

Read the “Lessons from the Supply Chain” report to get an insight into how sourcing challenges during the pandemic is changing attitudes to risk in the supply chain, and ultimately changing the shape of the supply chain itself.

Key takeaways

  • Tensions over vaccine supply timelines emphasize the importance of drafting clear contracts.
  • Claims arise when pharma products fall outside of set parameters, such as temperature limits, during transit.
  • If a shipment’s value includes research and development (R&D) costs, liability can become contentious.
  • From governments to corporates, diversification of suppliers and near-shoring are being discussed.

Lessons from the Supply Chain

 

Read more reports in the ‘Life Science in the era of pandemics’ series:

Making Medical Devices During a Pandemic
Fighting COVID-19 with genomics
The Great Telehealth Experiment
Emerging Risks in COVID-19 Clinical Trials

© 2021 Chubb. All rights reserved.

No part of this article may be reproduced in any written, electronic, recording, or printed form without written permission of Chubb.

Disclaimer - The content of the above article is not intended to constitute professional advice. Although all content is believed to be accurate, Chubb Insurance Singapore Limited (Chubb) makes no warranty or guarantee about the accuracy, completeness, or adequacy of the content of this article. Users relying on any content do so at their own risk.

Tips and Resources

We help you stay ahead and informed with these helpful tips and tricks

Have a question or need more information?

Contact us to find out how we can help you get covered against potential risks